Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. is a diagnostics technology company focused on expanding access to molecular diagnostic testing, particularly in transplanted organ rejection testing. The company develops molecular diagnostic test kits that allow customers to perform tests in-house, differing from the central laboratory model where samples are sent out for testing. This decentralized approach also supports researchers by enabling more studies. Insight Molecular Diagnostics Inc.'s initial target customers include hospitals, transplant centers, and laboratories. Key decision-makers for deploying their tests include doctors such as surgeons, nephrologists, and oncologists, as well as researchers, pathologists, lab directors, medical directors, department heads, lab managers, and chief medical officers. The company maintains a science-driven organization and generates intellectual property in its strategic target markets. Its intellectual property portfolio covers three main areas: organ transplant, oncology therapy selection, and oncology therapy monitoring. Within these categories, Insight Molecular Diagnostics Inc. has developed or is developing laboratory developed tests (LDTs) run at its Franklin, Tennessee laboratory, kitted research use only (RUO) tests, and in vitro diagnostic (IVD) kitted clinical tests for local labs. The primary near-term strategic market is organ transplant, where the company aims to provide a molecular diagnostic test kit for clinical use that decentralizes access to organ health testing for transplant patients. Enabling in-house testing is expected to create new value in the approximately $2 billion addressable market for kitted transplant rejection testing.